If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-30. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
The two substrates of this enzyme are (5β)-pregnan-21-ol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are (5β)-pregnan-21-al, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 21-hydroxysteroid:NAD+ 21-oxidoreductase. This enzyme is also called 21-hydroxysteroid dehydrogenase (NAD+).
==== Charge rate ==== The company's planned 2025 batteries were projected to have a peak charging rate of 350kW and a service life of 1000 fast-charging cycles. StoreDot battery cells require liquid cooling within each cell during fast charging. StoreDot announced their 2025 batteries would charge at a rate that adds 100 miles in 5 minutes for a vehicle that uses 14kWh per 100 kilometers, which corresponds to a charging rate of 270kW. StoreDot had been developing faster-charging cells that charge a 75kWh battery 70% in 10 minutes (from 10% to 80%) which corresponds to a charging rate of 315kW, which it aimed to deliver in 2026. StoreDot stated in 2026 it needs two more years of development in order to commercialize its product.
== Motivation == FTIR is a method of measuring infrared absorption and emission spectra. For a discussion of why people measure infrared absorption and emission spectra, i.e. why and how substances absorb and emit infrared light, see the article: Infrared spectroscopy.
=== Netherlands === "Half-om-halfgehakt" (half for half minced meat) is commonly used for mixed minced meat, made of equal amounts of beef and pork. The term "Gehacktes halb und halb" is used in Germany, also referring to minced meat.
Sources: en.wikipedia.org
Mick Anglo (born Maurice Anglowitz, 19 June 1916 – 31 October 2011) of Russian Jewish ancestry, was a British comic book writer, editor and artist, as well as an author. He is best known for creating the superhero Marvelman, later known as Miracleman, a character later revived in 1982 in a dark, post-modern reboot by writer Alan Moore, with later contributions by Neil Gaiman. Lisa Appignanesi (born 4 January 1946) writer, novelist, campaigner for free expression; was Chair of the Royal Society of Literature; former President of English PEN; Chair of Freud Museum; chaired 2017 Booker International Prize; Honorary Fellow of St Benet's Hall, Oxford and visiting professor in the Department of English at King's College London, and held a Wellcome Trust; has written for The New York Review of Books, The Guardian and The Observer, as well as making programmes and appearing on the BBC; was Director of Talks and Seminars at the Institute of Contemporary Arts (ICA) in London; was made a Chevalier of the Ordre des Arts et des Lettres and was appointed Officer of the Most Excellent Order of the British Empire (OBE) in the 2013 New Year Honours for services to literature. She became a Fellow of the Royal Society of Literature in 2015 and became the Chair of the Royal Society of Literature Council in 2016. Neal Ascherson (born 5 October 1932) journalist and writer; described by Radio Prague as "one of Britain's leading experts on central and eastern Europe".
==== Non-seasonal depression ==== Light therapy has also been suggested in the treatment of non-seasonal depression and other psychiatric mood disturbances, including major depressive disorder, bipolar disorder and postpartum depression. A meta-analysis by the Cochrane Collaboration concluded that "for patients suffering from non-seasonal depression, light therapy offers modest though promising antidepressive efficacy." A 2008 systematic review concluded that "overall, bright light therapy is an excellent candidate for inclusion into the therapeutic inventory available for the treatment of nonseasonal depression today, as adjuvant therapy to antidepressant medication, or eventually as stand-alone treatment for specific subgroups of depressed patients." A 2015 review found that supporting evidence for light therapy was limited due to serious methodological flaws. A 2016 meta-analysis showed that bright light therapy appeared to be efficacious, particularly when administered for 2–5 weeks' duration and as monotherapy.
=== Ifosfamide toxicity === Another use of methylene blue is to treat ifosfamide neurotoxicity. Methylene blue was first reported for treatment and prophylaxis of ifosfamide neuropsychiatric toxicity in 1994. A toxic metabolite of ifosfamide, chloroacetaldehyde (CAA), disrupts the mitochondrial respiratory chain, leading to an accumulation of nicotinamide adenine dinucleotide hydrogen (NADH). Methylene blue acts as an alternative electron acceptor, and reverses the NADH inhibition of hepatic gluconeogenesis while also inhibiting the transformation of chloroethylamine into chloroacetaldehyde, and inhibits multiple amine oxidase activities, preventing the formation of CAA. The dosing of methylene blue for treatment of ifosfamide neurotoxicity varies, depending upon its use simultaneously as an adjuvant in ifosfamide infusion, versus its use to reverse psychiatric symptoms that manifest after completion of an ifosfamide infusion. Reports suggest that methylene blue, up to six doses a day, has resulted in improvement of symptoms within 10 minutes to several days. Alternatively, it has been suggested that intravenous methylene blue every six hours for prophylaxis during ifosfamide treatment in people with history of ifosfamide neuropsychiatric toxicity. Prophylactic administration of methylene blue the day before initiation of ifosfamide, and three times daily during ifosfamide chemotherapy has been recommended to lower the occurrence of ifosfamide neurotoxicity.
=== Cell Selection & Expansion === IBA has developed an affinity chromatography system for non-magnetic isolation of peripheral blood mononuclear cells, T cells, B cells and other cells of interest. This technology is known as Fab-TACS (Traceless Affinity Cell Selection) and is based on Strep-tagged Fab fragments, which reversibly capture and release the target cells. This delivers label-free, non-activated cells suitable for immunologic or cell biological assays. The technology can be used with manual gravity flow columns as well as with the automated cell selection device FABian. Isolated and purified cells are being deployed for basic research as well as diagnostic applications. The Streptamers for cell expansion enable the controlled stimulation of T cells. They consist of non-magnetic soluble protein complexes generated by multimerization of αCD3- and αCD28 Fab-Streps with a Strep-Tactin multimer. The reversible reagents can be easily removed from the cells by the addition of biotin. This allows to regulate the extent of stimulation precisely and to study functional and label-free activated T cells.
Crenarchaeol is mainly attributed to ammonium-oxidizing Nitrososphaerota and has four cyclopentane rings plus one cyclohexane ring, which distinguishes it from GDGT-4 and is unique to the Nitrososphaerota phylum. The evolution of the cyclohexane ring was likely to adjust the density of the membrane packing to more optimally function at the cooler ocean temperatures to which Nitrososphaerota adapted. Due to their structural similarities, crenarchaeol and GDGT-4 have similar GC/MS elution times. They are similar in prevalence to GDGT-0 and therefore are not included in the TEX86 paleothermometer because their abundance overwhelms the less abundant GDGT groups. A crenarchaeol regioisomer, however, is a part of the TEX86 paleothermometer. This isomer likely differs by having a cis configuration on the cyclopentane ring neighboring the additional cyclohexane ring. It is presumed to be also made by Nitrososphaerota.
Sources: en.wikipedia.org
=== Articles === Ben-Amos, I.K. (1997). "Human Bonding: Parents and Their Offspring in Early Modern England." Discussion Papers in Economic and Social History – Oxford University. Brown, S.L. & Brown, R.M. (2006). Selective investment theory: Recasting the functional significance of close relationships. Psychological Inquiry, 17, 1–29. – a theoretical proposal that "human social bonds evolved as overarching, emotion regulating mechanisms designed to promote reliable, high-cost altruism among individuals who depend on one another for survival and reproduction" (From the abstract) Immerman, R.S. & Mackey, W.C. (2003). Perspectives on Human Attachment (Pair Bonding): Eve's unique legacy of canine analogue Evolutionary Psychology, 1, 138–154. ISSN 1474-7049 Thorne, L. (2006). "Of Human Bonding" – Condo Dwellers Find Cool Ways to Connect With the Neighbors, Express (Washingtonpost.com), Mon., (7 Aug.)
A few of the latter are so rare that they were not discovered in nature, but were synthesized in the laboratory before it was determined that they exist in nature: technetium (element 43), promethium (element 61), astatine (element 85), neptunium (element 93), and plutonium (element 94). No element heavier than einsteinium (element 99) has ever been observed in macroscopic quantities in its pure form, nor has astatine; francium (element 87) has been only photographed in the form of light emitted from microscopic quantities. Of the 94 natural elements, eighty have a stable isotope and one more (bismuth) has an almost-stable isotope (with a half-life of 2.01×1019 years, over a billion times the age of the universe). Two more, thorium and uranium, have isotopes undergoing radioactive decay with a half-life comparable to the age of the Earth. The stable elements plus bismuth, thorium, and uranium make up the 83 primordial elements that survived from the Earth's formation. The remaining eleven natural elements decay quickly enough that their continued trace occurrence rests primarily on being constantly regenerated as intermediate products of the decay of thorium and uranium. All 24 known artificial elements are radioactive.
Majority (about 70% to 80%) is converted to bicarbonate ions (HCO3–) by the enzyme carbonic anhydrase in the red blood cells, by the reaction: CO2 + H2O → H2CO3 → H+ + HCO3– 5–10% is dissolved in blood plasma 5–10% is bound to hemoglobin as carbamino compounds Hemoglobin, the main oxygen-carrying molecule in red blood cells, carries both oxygen and carbon dioxide. However, the CO2 bound to hemoglobin does not bind to the same site as oxygen. Instead, it combines with the N-terminal groups on the four globin chains. However, because of allosteric effects on the hemoglobin molecule, the binding of CO2 decreases the amount of oxygen that is bound for a given partial pressure of oxygen. This is known as the Haldane Effect, and is important in the transport of carbon dioxide from the tissues to the lungs. Conversely, a rise in the partial pressure of CO2 or a lower pH will cause offloading of oxygen from hemoglobin, which is known as the Bohr effect.
Keller also plans on opening his own burger restaurant inspired by his Los Angeles experience of In-N-Out. Julia Child, one of the first celebrities to champion the chain, admitted to knowing every location of the restaurant between Santa Barbara and San Francisco. Child also had the burgers delivered to her during a hospital stay. Anthony Bourdain reportedly said that In-N-Out was his favorite fast food meal, later naming the restaurant as "the best restaurant in Los Angeles". Ina Garten at an interview at Today show said "I have to say, I don't eat fast food at all, with one exception. When we're in California doing book tours, we always have to go to In-N-Out Burger. It's so good and I know it was Julia Child's favorite too, so it's okay." In-N-Out was one of the few restaurant chains mentioned positively in the book Fast Food Nation. The book commended the chain for using natural and fresh ingredients and for looking after the interests of employees regarding pay and benefits. An In-N-Out food truck catered Vanity Fair's 2012 Academy Awards after party.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.